Cetuximab-related Hypersensitivity Reactions in Northeast Tennessee
Primary Objective: To confirm the findings of several small studies conducted in the southeastern United States showing hypersensitivity infusion reaction (HIR) rates as high as 22% with the monoclonal antibody, cetuximab. Although well known for a risk of HIRs, early clinical studies showed much lower reaction rates of 3%.
Angles, M.; and Bossaer, John B.. 2012. Cetuximab-related Hypersensitivity Reactions in Northeast Tennessee. Trainee Mentored Presentation. Hematology Oncology Pharmacy Association Annual Meeting, Orlando, FL. http://www.hoparx.org/annual-conference/handouts-abstract-archive